cancers Brief Report Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019 Jean-Bernard Auliac 1,* , Sophie Bayle 2, Pascal Do 3, Gwenaëlle Le Garff 4, Magali Roa 5, Lionel Falchero 6, Eric Huchot 7 , Gilles Quéré 8 , Gaëlle Jeannin 9, Anne-Cécile Métivier 10, Joëlle Hobeika 1, Florian Guisier 11 and Christos Chouaid 1 1 Department of Pneumology, CHI de Créteil, 94000 Créteil, France;
[email protected] (J.H.);
[email protected] (C.C.) 2 Department of Pneumology, CHU de Saint-Etienne, 42055 Saint-Etienne, France;
[email protected] 3 Department of Pneumology, Centre Baclesse, 14076 Caen, France;
[email protected] 4 Department of Pneumology, CH de Saint Brieuc, 22027 Saint-Brieuc, France; gwenaelle.legarff@ch-stbrieuc.fr 5 Department of Pneumology, CHI de de Fréjus Saint Raphael, 83600 Fréjus, France;
[email protected] 6 Department of Pneumology, Hôpital Nord Ouest de Villefranche-sur-Saône, 69400 Gleizé, France;
[email protected] 7 Department of Pneumology, CHU Réunion Site Sud, 97448 Saint-Pierre, France;
[email protected] 8 Department of Pneumology, CHU de Brest, 29200 Brest, France;
[email protected] 9 Department of Pneumology, CHU de Clermont-Ferrand, 63000 Clermont-Ferrand, France;
[email protected] 10 Department of Pneumology, Hôpital Foch, 92150 Suresnes, France;
[email protected] 11 Department of Pneumology, CHU Charles Nicolle, 76000 Rouen, France; fl
[email protected] * Correspondence:
[email protected] Received: 6 November 2020; Accepted: 30 November 2020; Published: 2 December 2020 Simple Summary: Mutations of the BRAF oncogene are reported in tumors of patients with non-small-cell lung cancer in 2–4% of cases (about half of them are V600E mutation).